- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Chalk powder instead of medicines: Telangana drug controller issues alert against drugs by Meg Lifesciences
Telangana: In a significant move to curb the menace of falsified drugs, the Drugs Control Administration, Telangana, has issued a Spurious Drug Alert and Stop Use Notice for all drugs claiming to be manufactured by 'Meg Lifesciences.'
Telangana Drug Control Administration has become aware that certain drugs claimed on the label as manufactured by 'Meg Lifesciences, Khasara No. 47/5, Palli Gaon, Distt. Sirmour, 173 001' are being circulated in the market after the recent raid conducted by the administration. Stocks worth Rs. 33.35 lakhs seized in the raid claimed to be manufactured by Meg Lifesciences. Cases have been registered against several offenders involved in this spurious drugs racket.
These drugs have been found to be falsified medicines, manufactured by anti-social elements, containing no active ingredient (‘Nil’ medicine). They have been found to contain chalk powder and starch, posing significant health risks to consumers.
Certain Spurious Drugs claimed on the label as manufactured by Meg Lifesciences (Fictitious/Non-existent Company) seized by DCA, Telangana are MPOD-200 Tablets (Cefpodoxime Proxetil and Lactic Acid Bacillus tablets), MEXCLAV 625 Tablets (Amoxicillin & Potassium Clavulanate Lactic Acid Bacillus tablets), Cefoxim-CV Tablets (Cefpodoxime Proxetil & Potassium Clavulanate Lactic Acid Bacillus tablets).
"Consumers and healthcare professionals are informed to STOP USE immediately - to discontinue the use of any drugs claiming to be manufactured by 'Meg Lifesciences.' Retailers and wholesalers are directed to STOP the sale and distribution of any drugs bearing the label of 'Meg Lifesciences,' and to inform the area Drugs Inspector immediately," Telangana DCA said in a press note.
Upon further investigation, it has been confirmed that 'Meg Lifesciences' is a fictitious/non-existent company.
Given the scenario, the Telangana DCA further urged the public to remain vigilant and report any information regarding the distribution or sale of drugs from this purported manufacturer, 'Meg Lifesciences. It provided a toll free number 1800- 599-6969, operational from 10:30 am to 5:00 pm on all working days, which can be used to report about the spurious drug.
For more details, check out the press note on:
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751